FibroBiologics, Inc. Common Stock (FBLG) Earnings Analysis

FibroBiologics, Inc. Common Stock (FBLG) next reports earnings on 2026-07-30, consensus EPS -0.93 USD. Last quarter (2026-04-30) it missed with EPS -1.33 USD vs -1.26 USD est (-5.6%). It has beaten estimates in 1/4 recent quarters (25%). Trailing P/E -0.09.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does FBLG next report earnings?

Next earnings date2026-07-30
Consensus EPS estimate-0.93 USD
Revenue estimaten/a

FBLG earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-30-1.33 USD-1.26 USD-5.6%Miss
2025-10-31-0.13 USD-0.1 USD-30%Miss
2025-07-31-0.12 USD-0.11 USD-9.1%Miss
2025-03-31-0.09 USD-0.1 USD+10%Beat

Beat rate: 1/4 (25%) over reported quarters with consensus data.

FBLG valuation and analyst view

Trailing P/E-0.09
Trailing EPS-8.36533 USD
Price / book0.64
Dividend yield0.00%
Market cap0.00B
Analyst consensusBuy (2 buy / 2 hold / 0 sell)

Related research pages

Frequently asked questions

When is FibroBiologics, Inc. Common Stock (FBLG)'s next earnings date?

FibroBiologics, Inc. Common Stock is next scheduled to report on 2026-07-30, with a consensus EPS estimate of -0.93 USD.

Did FBLG beat earnings last quarter?

In its 2026-04-30 report, FBLG posted EPS of -1.33 USD versus a -1.26 USD estimate — a miss of 5.6%.

What is FBLG's earnings track record?

Over the last 4 reported quarters with consensus data, FBLG beat estimates 1 times (25%).

What is FBLG's current P/E ratio and EPS?

FBLG trades at a trailing P/E of -0.09 on trailing EPS of -8.365330273807828 USD.

What do analysts rate FBLG?

Analyst consensus is "Buy" across 4 ratings (0 strong buy, 2 buy, 2 hold, 0 sell, 0 strong sell).